<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Healthereum LLC

    Healthereum LLC

    The Healthereum Patient Behavior Management platform is a full cycle communication...

    The Healthereum Patient Behavior Management pla...

    Filing Type:    CF
    Mersana Therapeutics, Inc.

    Mersana Therapeutics, Inc.

    Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...

    Mersana Therapeutics is a clinical-stage biopha...

    Filing Type:    PU
    Marker Therapeutics, Inc.

    Marker Therapeutics, Inc.

    We are a clinical-stage immuno-oncology company specializing in the development an...

    We are a clinical-stage immuno-oncology company...

    Filing Type:    PU
    Alnylam Pharmaceuticals, Inc.

    Alnylam Pharmaceuticals, Inc.

    Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...

    Alnylam is leading the translation of RNA inter...

    Filing Type:    PU
    scPharmaceuticals Inc.

    scPharmaceuticals Inc.

    scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing...

    scPharmaceuticals is a clinical-stage pharmaceu...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Agios Pharmaceuticals, Inc.

    Agios Pharmaceuticals, Inc.

    Agios is a biopharmaceutical company passionately committed to applying our scient...

    Agios is a biopharmaceutical company passionate...

    Filing Type:    PU
    Sutro Biopharma, Inc.

    Sutro Biopharma, Inc.

    Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discover...

    Sutro Biopharma, located in South San Francisco...

    Filing Type:    PU
    MorphoSys AG

    MorphoSys AG

    MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...

    MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.